Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUAD: Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01297764Phase 2Active, not recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Apr 2011
- Primary completion
- Jun 2027
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, lenalidomide, vorinostat, dexamethasone in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Started Apr 2011; status: active, not recruiting.
02
Drugs
carfilzomiblenalidomidevorinostatdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01297764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297764.